Urokinase and its Receptor: Markers of Malignancy?

  • Patrick J. Gaffney
  • David A. Cooke
  • Kevin G. Burnand
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 360)


For many years it has been known that abnormal coagulation and fibrinolytic activity existed in the environs of malignant tumours. Whether these activities affected the invasiveness and metastatic activity of tumours has been in question for some time. The advent of precise assays for individual components of both coagulation and fibrinolysis has allowed a more precise analysis of the individual components of those systems which seem relevant to malignancy. While this report may not seem to fit ideally into an international meeting on Arterial Chemoreception it is felt that a wider perspective on receptors in disease may not go amiss. Thus we present herein a brief overview on the role of one component of the human fibrinolytic system, urinary-type plasminogen activator, uPA (also known as urokinase in the UK) and its receptor, called uPA receptor (e.g. u-PAR) in human malignancy. A brief comment is also given on a role for tissue plasminogen activator (tPA) in malignancy.


Breast Cancer Breast Tumour Tissue Plasminogen Activator Fibrinolytic Activity Disease Free Interval 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Astedt, B. &Holmberg, L. (1976). Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 261: 595–597.PubMedCrossRefGoogle Scholar
  2. Behrendt, N., Ronne, E., Ploug, M. et al. (1990). The human receptor for urokinase plasminogen activator. NH2 terminal amino acid sequence and glycosylation variants. J. Biol. Chem. 265: 6453–6460.PubMedGoogle Scholar
  3. Cubellis, M. V., Nolli, M. L., Cassani, G. &Blasi, F. (1986). Binding of single chain prourokinase to the urokinase receptor of human U937 cells. J. Biol. Chem. 261: 15819–15822.PubMedGoogle Scholar
  4. Duffy, M. J. (1993). Urokinase-type plasminogen activator and malignancy - Review. Fibrinolysis 7: 295–302.CrossRefGoogle Scholar
  5. Ellis, V., Scully, M. F. &Kakkar, V. V. (1989). Plasminogen activator initiated by single-chain urokinasetype plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem. 264: 2185–2188.PubMedGoogle Scholar
  6. Evers, J. L., Patel, J., Madeja, J. et al. (1982). Plasminogen activator activity composition in human breast cancer. Cancer Res. 42: 219–226.PubMedGoogle Scholar
  7. Ganesh, S., Verspaget, H., Sier, C. et al. (1992). Prognostic relevance of mucosal plasminogen activator levels in colorectal cancer. Fibrinolysis 6: (Suppl. 2), 103.Google Scholar
  8. Gelister, J., Mahmoud, M., Lewin, M. R., Gaffney, P. J. &Boulos, P. B. (1986). Plasminogen activators in human colorectal neoplasms. Br. Med. J. 293: 728–731.CrossRefGoogle Scholar
  9. Gorelik, E. (1992). Protective effect of fibrin on tumour metastasis. Fibrinolysis 6: (Suppl. 1), 35–38.CrossRefGoogle Scholar
  10. Hasui, Y., Marutsuka, K., Suzumiya, J. et al. (1992). The content of urokinase-type plasminogen activator as a prognostic factor in urinary bladder cancer. Int. J. Cancer 50: 871–873.PubMedCrossRefGoogle Scholar
  11. Janicke, F., Schmitt, M., Ulm, K., Gossner, W. &Graeff, H. (1989). Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet ii: 1049.CrossRefGoogle Scholar
  12. Layer, G. T., Cederholm-Williams, S. A., Gaffney, P. J. et al. (1987). Urokinase - the enzyme responsible for invasion and metastasis in human breast carcinoma. Fibrinolysis 1: 237–240.CrossRefGoogle Scholar
  13. Oka, T., Ishida, T., Nishino, T. &Sugimachi, K. (1991). Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumours of pulmonary adenocarcinoma. Cancer Res. 51:3522–3525.PubMedGoogle Scholar
  14. Plow, E. F., Freaney, D. E., Plescia, J. &Miles, L. A. (1986). The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol. 103: 2411–2420.PubMedCrossRefGoogle Scholar
  15. Roldan, A. L., Cubellis, M. V., Masucci, M. T. et al. (1990). Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin-dependent proteolysis. EMBO J. 9: 467–474.PubMedGoogle Scholar
  16. Tryggvason, K., Hoyhtya, M. &Salo, T. (1987). Proteolytic degradation of extracellular matrix in tumour invasion. Biochim. Biophys. Acta 907: 191–217.PubMedGoogle Scholar
  17. Vassali, J.-D., Baccino, D. &Berlin, D. (1985). A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100: 86–92.CrossRefGoogle Scholar
  18. Yu, H. &Schultz, R. M. (1990). Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and artisense genes. Cancer Res. 50: 7623–7633.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Patrick J. Gaffney
    • 1
  • David A. Cooke
    • 2
  • Kevin G. Burnand
    • 2
  1. 1.Division of HaematologyNational Institute for Biological Standards and ControlPotters Bar, HertfordshireUK
  2. 2.Department of SurgerySt Thomas’ HospitalLondonUK

Personalised recommendations